The Epstein-Barr virus is one of the most common and persistent human viruses in the world, according to the CDC.

The FDA has approved Gammagard Liquid ERC as a replacement therapy for PI in adult and pediatric patients 2 years of age and older.

Toxoplasma gondii is a widespread parasite responsible for toxoplasmosis, an infection that often lacks clear symptoms but ...

The approval of GAMMAGARD LIQUID ERC reinforces our commitment to supporting individualized treatment approaches for people with primary immunodeficiency, including a therapeutic option that has the ...

The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous ...

Global Phase 3 PROMINENT study will evaluate the efficacy and safety of felzartamab, as compared to tacrolimus, in adults with primary membranous nephropathy (PMN)There are currently no therapies spec ...

Highlights The acquisition combines IgA antibody assets and expertise of Boston-based TigaTx with Epsilogen’s assets and expertise in IgE to create the world ...

The acquisition combines IgA antibody assets and expertise of Boston-based TigaTx with Epsilogen’s assets and expertise in IgE to create the world’s leading pan-isotype cancer antibody company ...

A new antibody testing strategy using tissue transglutaminase antibodies at 6.1 times the upper limit of normal can improve celiac disease diagnosis in patients with T1D, according to a Swiss study.

Eliem Therapeutics is continuing its transformation into an immune-mediated disease company by paying $9 million to license a Chinese biotech’s IgA nephropathy antibody. Today’s deal with ...

Scientists at UMC Utrecht have developed a new technology to efficiently isolate a specific subset of gut bacteria from fecal samples that are recognized by IgA antibodies. These "IgA-coated" bacteria ...

Felzartamab, an investigational antibody, reduces triggers linked to IgA nephropathy, an autoimmune kidney disease, suggesting lasting clinical benefits.